Absci Corp (ABSI NASDAQ) stock market data APIs
$2.6887
-0.09(-3.3%)
as of September 16, 2025
Try our APIs with
free plan!
Absci Corp Financial Data Overview
Price chart is built with
Anychart
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Prev. Close
2.6887
Open
2.5975
High
2.7178
Low
2.575
52 wk Range
2.01-6.33
Market Cap
404 M
Shares Outstanding
150 M
Revenue
4 138 K
EPS
-0.24
Beta
2.021
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Absci Corp (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Absci Corp data using free add-ons & libraries
Get Absci Corp Fundamental Data
Absci Corp Fundamental data includes:
- Net Revenue: 4 138 K
- EBITDA: -103 730 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.21
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Absci Corp News
New
Absci Corporation Taps Advanced Micro Devices Inc. (AMD) Chip for AI Drug Discovery Platform
Advanced Micro Devices Inc. (NASDAQ:AMD) is one of the best tech stocks to buy, according to Cathie Wood. On September 11, Absci Corporation (ABSI), a clinical-stage biotechnology firm, announced a st...
Absci (ABSI) Valuation in Focus Following Partnership With Oracle Cloud and AMD for AI Drug Discovery
If you are trying to figure out what comes next for Absci (ABSI), this recent wave of news might have you leaning forward. The company’s announcement of a strategic alliance with Oracle Cloud Infras...
Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD
Absci Corporation; Oracle; AMD Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs AUSTIN, Texas and VAN...
Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg
VANCOUVER, Wash. and NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced that w...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
